Dr. Guru Sonpavde, MD (Clinical Assistant Professor, Baylor College of Medicine) reported about an open label, phase II trial of sunitinib (Sunitinib, marketed as Sutent, and previously known as SU11248 is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and [...]
A study from Milan Italy look at the controversy, does the testosterone level achieved with androgen-deprivation therapy (ADT) increase the survival in men with metastatic prostate cancer? ADT comes with significant morbidity issues, so is there an adequate benefit from ADT (does it provide survival benefits) to balance out the negative side effects? This [...]
A multi-center Phase III study discussed at the 2009 meeting of the American Urological Association,[1] has demonstrated that the risk for bone fractures in men on androgen deprivation therapy (ADT) can be reduced by using toremifene (Acapodene). Men, fighting advanced prostate cancer, often receive long-term ADT, which along with other side effects will increase their [...]
Confirming a belief of many of us, new research has found that hormone therapy (endocrine therapy or ADT) is associated with a very large increased risk of developing various major heart problems. This research also tells us that some therapy options have a higher risk profile than others. At Europe's biggest cancer congress, ECCO 15 [...]
The September issue of The Journal of Nuclear Medicine published a study that shows that positron emission tomography (PET)/computer tomography (CT) scans using the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some men who have had prostatectomy. Men who elect to have a radical prostatectomy to treat prostate [...]